• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treatment of Modifiable Risk Factors Is Associated With Decrease in Coronary Heart Disease Incidence: Time to Use the Polypill.对可改变的危险因素进行治疗与冠心病发病率降低相关：是时候使用复方制剂了。
J Clin Hypertens (Greenwich). 2016 Sep;18(9):840-2. doi: 10.1111/jch.12827. Epub 2016 Apr 20.
2
Future of polypill use for the prevention of cardiovascular disease and strokes.未来用于预防心脑血管疾病和中风的复方药。
Am J Cardiol. 2014 Aug 15;114(4):641-5. doi: 10.1016/j.amjcard.2014.05.049. Epub 2014 Jun 6.
3
Polypill strategy for primary prevention of cardiovascular disorders.心血管疾病一级预防的多效药丸策略。
Drugs Today (Barc). 2013 May;49(5):317-24. doi: 10.1358/dot.2013.49.5.1950148.
4
The polypill in the primary prevention of cardiovascular disease.复方药在心血管疾病一级预防中的应用。
Fundam Clin Pharmacol. 2010 Feb;24(1):29-35. doi: 10.1111/j.1472-8206.2009.00795.x. Epub 2009 Nov 23.
5
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.一项基于复方药丸策略改善高危心血管疾病人群接受既定预防治疗的实用随机试验。
Eur J Prev Cardiol. 2015 Jul;22(7):920-30. doi: 10.1177/2047487314530382. Epub 2014 Mar 27.
6
Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.复方制剂：中低收入国家预防心血管疾病的一种经济可行策略。
Ther Adv Cardiovasc Dis. 2018 Jun;12(6):169-174. doi: 10.1177/1753944718764588. Epub 2018 Mar 16.
7
Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.使用复方制剂进行心血管疾病预防的优势与局限
Curr Cardiol Rep. 2017 May;19(5):45. doi: 10.1007/s11886-017-0853-y.
8
Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.用于预防心血管疾病的复方制剂的影响及可接受性的过程评估
BMJ Open. 2015 Sep 30;5(9):e008018. doi: 10.1136/bmjopen-2015-008018.
9
The evening versus morning polypill utilization study: the TEMPUS rationale and design.晚间与晨间复方制剂使用研究：TEMPUS的基本原理与设计
Eur J Prev Cardiol. 2014 Apr;21(4):425-33. doi: 10.1177/2047487313476961. Epub 2013 Feb 4.
10
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.复方药丸用于心血管疾病一级预防：世界卫生组织的可行性研究。
Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.

引用本文的文献

1
The polypill approach - An innovative strategy to improve cardiovascular health in Europe.多效药丸方案——改善欧洲心血管健康的创新策略。
BMC Pharmacol Toxicol. 2017 Feb 7;18(1):10. doi: 10.1186/s40360-016-0102-9.
2
Whole-Body Imaging Procedures in Resistant Hypertension: Evaluating for Secondary Causes or to Define End-Organ Damages?顽固性高血压的全身成像检查：用于评估继发性病因还是确定靶器官损害？
J Clin Hypertens (Greenwich). 2017 Jan;19(1):23-25. doi: 10.1111/jch.12918. Epub 2016 Oct 19.

本文引用的文献

1
Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension.复方药在预防心血管疾病和高血压中的作用。
Curr Hypertens Rep. 2016 Feb;18(2):14. doi: 10.1007/s11906-016-0624-y.
2
Trends in Modifiable Risk Factors Are Associated With Declining Incidence of Hospitalized and Nonhospitalized Acute Coronary Heart Disease in a Population.人群中可改变的风险因素趋势与住院和非住院急性冠状动脉心脏病发病率的下降相关。
Circulation. 2016 Jan 5;133(1):74-81. doi: 10.1161/CIRCULATIONAHA.115.016960. Epub 2015 Nov 18.
3
Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.用于预防心血管疾病的复方制剂的影响及可接受性的过程评估
BMJ Open. 2015 Sep 30;5(9):e008018. doi: 10.1136/bmjopen-2015-008018.
4
The Polypill: From Promise to Pragmatism.多效药丸：从前景到务实
PLoS Med. 2015 Aug 11;12(8):e1001862. doi: 10.1371/journal.pmed.1001862. eCollection 2015 Aug.
5
Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.在英国使用复方制剂提高依从性对继发性心血管疾病预防的成本效益及公共卫生效益
BMJ Open. 2015 May 9;5(5):e007111. doi: 10.1136/bmjopen-2014-007111.
6
Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.患者与医疗服务提供者对澳大利亚初级卫生保健中采用复方制剂策略改善心血管疾病预防的看法：一项基于实用随机对照试验的定性研究
Circ Cardiovasc Qual Outcomes. 2015 May;8(3):301-8. doi: 10.1161/CIRCOUTCOMES.115.001483. Epub 2015 May 5.
7
Heart disease and stroke statistics--2015 update: a report from the American Heart Association.《2015年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17.
8
An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.心血管复方药是否具有经济效益？堪亚尼 GAP 试验的成本分析。
Med J Aust. 2014 Dec 11;201(11):671-3. doi: 10.5694/mja14.00266.
9
A polypill strategy to improve adherence: results from the FOCUS project.多药复方片策略提高依从性：FOCUS 项目结果。
J Am Coll Cardiol. 2014;64(20):2071-82. doi: 10.1016/j.jacc.2014.08.021. Epub 2014 Sep 1.
10
Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modelling study.六种风险因素对实现 25×25 非传染性疾病死亡率降低目标的贡献：一项建模研究。
Lancet. 2014 Aug 2;384(9941):427-37. doi: 10.1016/S0140-6736(14)60616-4. Epub 2014 May 2.

Treatment of Modifiable Risk Factors Is Associated With Decrease in Coronary Heart Disease Incidence: Time to Use the Polypill.

作者信息

Chrysant Steven G, Chrysant George S

机构信息

University of Oklahoma School of Medicine, Oklahoma City, OK.

INTEGRIS Baptist Medical Center, Oklahoma City, OK.

出版信息

J Clin Hypertens (Greenwich). 2016 Sep;18(9):840-2. doi: 10.1111/jch.12827. Epub 2016 Apr 20.

DOI:10.1111/jch.12827
PMID:27094347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8031858/
Abstract
摘要